Get the Stockscreener App
0.3288
1.88%
-0.0063
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Prophase Labs Inc stock is traded at $0.3288, with a volume of 680.89K.
It is down -1.88% in the last 24 hours and down -15.78% over the past month.
ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.
See More
Previous Close:
$0.3351
Open:
$0.3318
24h Volume:
680.89K
Relative Volume:
0.10
Market Cap:
$13.66M
Revenue:
$62.71M
Net Income/Loss:
$-10.48M
P/E Ratio:
-0.5219
EPS:
-0.63
Net Cash Flow:
$-13.77M
1W Performance:
-5.87%
1M Performance:
-15.78%
6M Performance:
-38.43%
1Y Performance:
-88.17%
1-Day Range:
$0.3207
$0.3449
1-Week Range:
$0.3085
$0.3599
52-Week Range:
$0.2179
$3.00
Prophase Labs Inc Stock (PRPH) Company Profile
Name
Prophase Labs Inc
Sector
Industry
Phone
(215) 345-0919
Address
711 STEWART AVE, SUITE 200, NEW YORK, PA
Compare PRPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRPH
Prophase Labs Inc
|
0.3288 | 13.87M | 62.71M | -10.48M | -13.77M | -0.63 |
|
TMO
Thermo Fisher Scientific Inc
|
499.99 | 184.10B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
211.80 | 149.66B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
645.55 | 51.03B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
121.63 | 33.56B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
191.15 | 32.73B | 15.70B | 1.24B | 2.01B | 6.91 |
Prophase Labs Inc Stock (PRPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-20-21 | Initiated | H.C. Wainwright | Buy |
| Oct-13-21 | Downgrade | Dawson James | Buy → Neutral |
| Jan-20-21 | Initiated | Dawson James | Buy |
Prophase Labs Inc Stock (PRPH) Latest News
ProPhase Labs announces closing of $3M senior secured convertible notes - MSN
ProPhase Labs, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:PRPH) - Seeking Alpha
ProPhase Labs Achieves Key U.S. Patent for Test - MSN
Prophase Labs Files Proxy, Reschedules Shareholder Meeting - TipRanks
ProPhase Labs Announces Filing of Definitive Proxy Statement and New Date for Special Meeting of Shareholders - GlobeNewswire
ProPhase Labs Announces New Date for Special Meeting of Shareholders. - AInvest
1 Billion Shares: ProPhase Labs Plans Major Expansion into Bitcoin Strategy and $15M Buyback Program - Stock Titan
What makes ProPhase Labs Inc. stock price move sharplyEarnings Risk Report & Risk Adjusted Buy and Sell Alerts - classian.co.kr
ProPhase Labs Inc (PRPH) Q2 2025 Earnings Call Highlights: Strategic Moves and Future Prospects - Yahoo Finance
Prophase Labs, Inc. shares fall 8.11% premarket as federal budget cuts and VC funding into oncology ventures. - AInvest
What is ProPhase Labs Inc. s revenue forecastJuly 2025 Intraday Action & Daily Market Momentum Tracking - 선데이타임즈
Why did PRPH's Q4 2024 earnings surprise analysts? - AInvest
Volume Surge May Signal Institutional Interest in ProPhase Labs Inc.Trade Risk Assessment & Free AI Powered Buy and Sell Recommendations - sundaytimes.kr
Can ProPhase Labs Inc. deliver alphaCPI Data & Precise Swing Trade Alerts - thegnnews.com
ProPhase Labs announces full USPTO approval for issuance of U.S. patent - MSN
Price Channel Expanding on ProPhase Labs Inc.’s ChartTrade Ideas & Daily Entry Point Trade Alerts - beatles.ru
Prophase Labs shares rise 2.14% intraday after earnings results presentation. - AInvest
ProPhase Labs 2025 Q2 Earnings Improved Losses Despite Revenue Decline - AInvest
ProPhase Labs Reports Turnaround and Strategic Growth - TipRanks
ProPhase Labs Q2 2025 Earnings Call Transcript - MarketBeat
ProPhase Labs' Q2 2025: Unraveling Contradictions in Cancer Test Strategies and Crypto Investments - AInvest
ProPhase Labs, Inc. SEC 10-Q Report - TradingView
Transcript : ProPhase Labs, Inc., Q2 2025 Earnings Call, Aug 13, 2025 - MarketScreener
Earnings call transcript: ProPhase Labs Q2 2025 reveals EPS beat, stock drops - Investing.com Canada
ProPhase Labs Inc. To Present Second Quarter 2025 Financial Results On August 13, 2025 - Barchart.com
ProPhase Labs, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
ProPhase Labs earnings beat by $0.04, revenue fell short of estimates - Investing.com Canada
ProPhase Labs Inc Reports Q2 2025 Earnings: EPS of $(0.11) Misses Estimate, Revenue Falls Short at $1.2 Million - GuruFocus
ProPhase Labs Posts Narrower Q2 Loss - The Motley Fool
ProPhase Labs Posts Narrower Q2 Loss - Nasdaq
ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 | PRPH Stock News - GuruFocus
Can ProPhase Labs Inc. expand into new marketsJuly 2025 Macro Moves & Real-Time Volume Surge Alerts - newsyoung.net
ProPhase Labs Announces Financial Results for the Three and Six Months Ended June 30, 2025 - GlobeNewswire
ProPhase Labs Reports Q2 2025 Earnings, Secures Patent for BE-Smart Esophageal Adenocarcinoma Risk Assessment Test, and Advances Multiple Non-Dilutive Liquidity Initiatives. - AInvest
Diagnostics Firm ProPhase Labs Reveals Triple Play: Cost Cuts, Cancer Test Patent, and Bitcoin Strategy - Stock Titan
ProPhase Labs shares fall 1.13% premarket after receiving USPTO approval for biomarker-driven systems. - AInvest
ProPhase Labs Schedules Q2 2025 Earnings Release and Conference Call - AInvest
ProPhase Labs Earnings Preview: Analysts Expect $-0.15 EPS, Shares Down 85.7% Over the Last Year - AInvest
What caused PRPH's earnings to drop in Q3 2024? - AInvest
How did PRPH's 2024 earnings trend evolve? - AInvest
What does PRPH's earnings volatility indicate? - AInvest
ProPhase Labs Seeks Enhanced Shareholder Value through Reverse Merger and Bitcoin Integration - AInvest
ProPhase Labs (PRPH.O) Surges Over 33% — What’s Behind the Sharp Intraday Move? - AInvest
PRPH.O Surges 29.75%: Tracing the Source of the Sudden Intraday Spike - AInvest
ProPhase Labs Surges 23.75%: Patent Grant and Earnings Call Spark Volatility - AInvest
ProPhase Labs (PRPH) Surges 27.76% on Patent Approval and BE-Smart Validation—What’s Next for This Biotech Play? - AInvest
ProPhase Labs stock soars after securing patent for esophageal disease test - Investing.com Nigeria
ProPhase Labs stock soars after securing patent for esophageal disease test By Investing.com - Investing.com South Africa
ProPhase Labs shares rise 35.82% premarket after receiving US patent for esophageal product. - AInvest
ProPhase Labs Gets US Patent For Esophageal Adenocarcinoma Risk Assessment; Shares Up Pre-Bell - MarketScreener
Why Is ProPhase Labs Stock (PRPH) Up 25% Today? - TipRanks
Prophase Labs Inc Stock (PRPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.05%
1.90%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):